ACUTE LYMPHOBLASTIC LEUKAEMIA
(ALL) TREATMENT IN CHINA

China combines several factors that matter specifically for ALL: deep CAR-T capacity across both approved products and trial platforms, mature paediatric and adult haematology programmes, well-established allogeneic transplant centres including haploidentical donor expertise, and access to immunotherapies such as blinatumomab and inotuzumab. The CAR-T ecosystem is particularly relevant — Chinese centres have treated thousands of B-ALL patients with CD19 CAR-T, and emerging CD22 and CD7 platforms now offer options for patients who relapse after CD19 therapy or have T-cell ALL. For families facing limited options at home, this depth often opens realistic pathways.

Frontline therapy Frontline ALL treatment is risk-adapted and typically follows a defined sequence: induction to achieve complete remission, consolidation, and maintenance. Paediatric-inspired regimens are increasingly used in adolescents and young adults because of better outcomes. Treatment intensity, choice of asparaginase preparation, central nervous system prophylaxis, and the need for transplant are guided by age, white cell count at diagnosis, immunophenotype, cytogenetics, and minimal residual disease (MRD) response after induction. Total duration is typically two to three years. Philadelphia-positive (Ph+) ALL For Ph+ ALL, tyrosine kinase inhibitors — imatinib, dasatinib, ponatinib — are added to chemotherapy or to chemotherapy-light regimens. Combinations of TKI with blinatumomab have produced strong outcomes in adults and are part of modern protocols. Allogeneic transplant in first remission is decided based on MRD response, donor availability, and patient fitness. MRD-guided decisions Minimal residual disease testing — by flow cytometry, PCR, or next-generation sequencing — is now central to ALL care. MRD status after induction and consolidation guides whether to intensify therapy, add immunotherapy such as blinatumomab to clear residual disease, or proceed to allogeneic transplant. CancerFax helps patients confirm that MRD testing is being done with appropriate sensitivity, especially when relapse risk is high. Targeted immunotherapies Blinatumomab — a CD19/CD3 bispecific T-cell engager — is widely used in China for MRD-positive disease, relapsed or refractory B-ALL, and as a bridge to transplant. Inotuzumab ozogamicin, an anti-CD22 antibody-drug conjugate, is another important option for relapsed B-ALL. Both are available in China and increasingly accessible to international patients, with biosimilar and lower-cost options expanding access. CAR-T cell therapy CAR-T cell therapy has transformed outcomes in relapsed or refractory B-ALL. China has multiple approved CD19 CAR-T products, plus a deep trial pipeline including CD22 CAR-T for CD19-relapsed disease, dual CD19/CD22 platforms, CD7 CAR-T for T-cell ALL (a uniquely active area in Chinese centres), and allogeneic off-the-shelf CAR-T programmes. Eligibility depends on age, antigen expression, disease burden, prior therapy, and organ function. CAR-T can serve as definitive therapy or as a bridge to allogeneic transplant depending on the case. Allogeneic bone marrow transplant Allogeneic transplant remains a curative option for high-risk and relapsed ALL. Chinese transplant centres have particularly strong experience with haploidentical (half-match) family donor transplants, which makes donor identification faster and more accessible than HLA-matched unrelated donor searches in many countries. Pre-transplant disease control with blinatumomab, inotuzumab, or CAR-T improves outcomes meaningfully. Clinical trials China runs one of the most active ALL trial pipelines globally, covering next-generation CAR-T constructs, allogeneic universal CAR-T platforms, novel bispecifics, and chemotherapy-sparing regimens. International patient access varies by trial and centre, and eligibility is strict. CancerFax helps patients pre-screen against realistic trial options.

Case review — diagnosis, subtype, MRD status, and prior treatment are reviewed urgently to assess whether China-based options are realistic. Hospital and trial matching — reports are shared with appropriate Chinese haematology, CAR-T, and transplant centres for structured feedback before any travel. Treatment planning — approved CAR-T products, trial platforms, immunotherapy bridges, and transplant pathways are mapped against the patient's case. Logistics — patients receive guidance on realistic cost ranges, expected stay duration, visa, accommodation, interpreter support, and follow-up planning. Continuity of care — communication with hospital teams, MRD monitoring, and post-treatment care after returning home are coordinated through a single point of contact.

Frequently Asked Questions

Answers to common questions from patients and families.